{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"4480"},{"groupId":"OG001","spread":"0.26","value":"7890"},{"groupId":"OG004","spread":"0.29","value":"5210"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"AUC0-8h was defined as the area under the concentration-time curve from dosing (time 0) of INCB001158 to 8 hours post-dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"},{"description":"INCB001158 was administered orally at 50 mg BID in combination with pembrolizumab at 200 mg IV Q3W to participants with moderately impaired renal function.","id":"OG004","title":"Part 1C: INCB001158 50 mg + Pembrolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only participants with available data were analyzed. Analysis was conducted to compare INCB001158 50 mg + pembrolizumab in participants with renal impairment with INCB001158 50 mg or 75 mg in participants with normal renal function. It was pre-specified to collect data for only the Part 1A INCB001158 50 mg, Part 1A: INCB001158 75 mg, and Part 1C: INCB001158 50 mg + Pembrolizumab arms. Participants in the INCB001158 100 mg and 150 mg arms did not contribute to the analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose","title":"AUC0-8h of INCB001158 in Participants With Renal Impairment (Part 1C) and Normal Renal Function (Part 1A)","type":"SECONDARY","unitOfMeasure":"hours x ng/mL"}